Paper · 28665128
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Brameld KA and 15 others. J Med Chem, 2017. Cited by 80 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Papers, record 28665128. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28665128
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Pyridones | Major topic |
| Pyrimidines | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Dogs | |
| Drug Design | |
| Drug Stability | |
| Female | |
| Humans | |
| Intestinal Absorption | |
| Macaca fascicularis | |
| Male | |
| Rats, Sprague-Dawley | |
| Receptor, Fibroblast Growth Factor, Type 1 | |
| Receptor, Fibroblast Growth Factor, Type 2 | |
| Receptor, Fibroblast Growth Factor, Type 3 | |
| Receptor, Fibroblast Growth Factor, Type 4 | |
| Solubility | |
| Structure-Activity Relationship |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,756,985 | A Scalable Design for Proximity-Inducing Molecules. | bioRxiv | 2026 | https://conductscience.org/library/papers/41756985 | PubMed |
| 41,226,200 | Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. | Molecules | 2025 | https://conductscience.org/library/papers/41226200 | PubMed |
| 40,430,355 | Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction. | Molecules | 2025 | https://conductscience.org/library/papers/40430355 | PubMed |
| 40,099,438 | Size-Dependent Target Engagement of Covalent Probes. | J Med Chem | 2025 | https://conductscience.org/library/papers/40099438 | PubMed |
| 39,856,676 | A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/39856676 | PubMed |
| 39,590,377 | Pharmacological and Biological Targeting of FGFR1 in Cancer. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39590377 | PubMed |
| 38,991,015 | Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRasG12C. | ACS Chem Biol | 2024 | https://conductscience.org/library/papers/38991015 | PubMed |
| 38,659,263 | Research Progress and Prospect of Nitrogen-containing Heterocycle in Anti-gastric Cancer Drugs: A Review. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/38659263 | PubMed |
| 38,172,256 | Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R. | Commun Chem | 2024 | https://conductscience.org/library/papers/38172256 | PubMed |
| 37,959,782 | Synthesis, Herbicidal Activity, Mode of Action, and In Silico Analysis of Novel Pyrido[2,3-d]pyrimidine Compounds. | Molecules | 2023 | https://conductscience.org/library/papers/37959782 | PubMed |
1 to 10 of 34
See all 34 cited byGenes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGFR1 | 2,260 | PubTator's text mining | https://conductscience.org/library/genes/2260 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| FGFR4 | 2,264 | PubTator's text mining | https://conductscience.org/library/genes/2264 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28665128
GET https://conductscience.org/api/papers/v1/28665128/cited_by?page=2